Company intelligence / Profile preview

Istesso

Ownership: Private
Development stage: Other

Overview

Istesso develops first-in-class small molecule drugs that harness the body’s natural adaptive repair mechanisms to treat chronic diseases by repairing damaged tissue rather than just controlling symptoms. Their lead candidate, leramistat, has shown promising results in repairing bone/joint damage in RA without immunosuppression and also targets lung scarring in IPF. Leramistat has received FDA Fast Track and Orphan Drug Designation for IPF. The company’s approach represents a novel paradigm shift from disease management to programmed disease resolution.

Therapeutic areas: OtherImmunologyPulmonologyRheumatology
Modalities: Small molecules (noted as "once-daily pill" and drug-like compounds)
Industry: Biotech

Drug pipeline

3 assets

Leramistat

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Istesso.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Istesso.

Explore the full profile